Windsor Advisory Group’s AbbVie ABBV Stock Holding History

Windsor Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$268K	Sell	1,232 -103	-8%	-$22.8K	0.22%	45
2025 Q4	$305K	Hold	1,335	–	–	0.27%	43
2025 Q3	$309K	Hold	1,335	–	–	0.27%	49
2025 Q2	$248K	Hold	1,335	–	–	0.35%	35
2025 Q1	$280K	Sell	1,335 -49	-4%	-$9.53K	0.36%	32
2024 Q4	$246K	Sell	1,384 -214	-13%	-$39.3K	0.29%	45
2024 Q3	$316K	Sell	1,598 -42	-3%	-$7.84K	0.36%	46
2024 Q2	$281K	Sell	1,640 -126	-7%	-$20.9K	0.56%	29
2024 Q1	$322K	Buy	1,766 +53	+3%	+$9.13K	0.91%	27
2023 Q4	$265K	Sell	1,713 -139	-8%	-$20.3K	0.79%	33
2023 Q3	$276K	Sell	1,852 -206	-10%	-$30.2K	0.66%	34
2023 Q2	$277K	Hold	2,058	–	–	0.69%	32
2023 Q1	$328K	Sell	2,058 -129	-6%	-$19.7K	0.79%	29
2022 Q4	$353K	Buy	+2,187	New	+$335K	0.94%	30

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Windsor Advisory Group's ABBV Position: Q1 2026 in Review

Windsor Advisory Group reduced its AbbVie (ABBV) stake by 7.7% in Q1 2026, selling an estimated $22.8K and leaving 1,232 shares worth $268K. The position accounts for 0.22% of the portfolio, ranked #45.

Windsor Advisory Group first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $353K in Q4 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Windsor Advisory Group held 1,232 shares of AbbVie worth $268K as of Q1 2026.
Windsor Advisory Group sold 103 AbbVie shares in Q1 2026, an estimated $22.8K.
AbbVie made up 0.22% of Windsor Advisory Group's portfolio in Q1 2026, its #45 holding.
Windsor Advisory Group first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Windsor Advisory Group's AbbVie position peaked at $353K in Q4 2022.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Windsor Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.